Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 470-470-3 | CAS number: 9022-75-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
LD50>2000 mg/kg bw in a limit test by oral route.
LD50>2000 mg/kg bw in a limit test by dermal route.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
Reference
None
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Well conducted and described study in accordance with GLP and OECD guideline 423 without any deviation.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Type of coverage:
- semiocclusive
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
Reference
Table 1: individual bodyweights
Dose (mg/kg) |
Sex |
Animals |
Day 1 |
Body weight gain |
Day 8 |
Body weight gain |
Day 15 |
2000 |
Male |
01 |
270 |
39 |
309 |
53 |
362 |
02 |
248 |
53 |
301 |
65 |
366 |
||
03 |
216 |
43 |
259 |
51 |
310 |
||
04 |
253 |
56 |
309 |
69 |
378 |
||
05 |
247 |
40 |
287 |
50 |
337 |
||
Mean |
247 |
46 |
293 |
58 |
351 |
||
SD |
20 |
8 |
21 |
9 |
27 |
||
2000 |
Female |
06 |
237 |
0 |
237 |
23 |
260 |
07 |
244 |
2 |
246 |
8 |
254 |
||
08 |
234 |
12 |
246 |
22 |
268 |
||
09 |
235 |
13 |
248 |
18 |
266 |
||
10 |
249 |
-2 |
247 |
7 |
254 |
||
Mean |
240 |
5 |
245 |
16 |
260 |
||
SD |
6 |
7 |
4 |
8 |
7 |
Table 2: cutaneaous reactions
Time |
Animals |
Cutaneous reactions |
|
Males |
Females |
||
D 2 |
5/5 |
5/5 |
None |
D 3 |
4/5 |
|
Discrete erythema |
1/5 |
2/5 |
Moderate erythema |
|
|
2/5 |
Severe erythema |
|
|
1/5 |
Moderate erythema, crusts |
|
D 4 |
|
2/5 |
Dryness of the skin,moderate erythema |
|
3/5 |
Moderate erythema |
|
2/5 |
|
Dryness of the skin,discrete erythema |
|
3/5 |
|
None |
|
D 5 |
2/5 |
1/5 |
Dryness of the skin |
|
1/5 |
Moderate erythema |
|
|
3/5 |
Dryness of the skin,discrete erythema |
|
3/5 |
|
None |
|
D 6 |
2/5 |
2/5 |
Dryness of the skin |
3/5 |
|
None |
|
|
3/5 |
Dryness of the skin, discrete erythema |
|
D 7 |
2/5 |
4/5 |
Dryness of the skin |
3/5 |
1/5 |
None |
|
D 8 and D 9 |
1/5 |
|
Crusts, dryness of the skin |
4/5 |
3/5 |
Dryness of the skin |
|
|
2/5 |
None |
|
D 10 and D 11 |
5/5 |
3/5 |
Dryness of the skin |
|
2/5 |
None |
|
D12 to D 15 |
5/5 |
5/5 |
None |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP study conducted in compliance with international guidelines without any deviation.
Additional information
In an acute oral class method toxicity study performed in accordance with GLP and OECD guideline 423, no mortality and no clinical signs were observed in Sprague Dawley rats given a single oral dose of Chimexane NV in purified water at the limit test dose of 2000 mg/kg bw.
In an acute dermal toxicity study performed in accordance with GLP and OECD guideline 402, no mortality was observed in Sprague Dawley rats given a single dose of Chimexane NV at the limit test dose of 2000 mg/kg bw.
Justification for selection of acute toxicity – oral endpoint
Only one study available for this endpoint
Justification for selection of acute toxicity – inhalation endpoint
The test substance is most of the time a pasty solid, so the potential for the generation of inhalable forms is unlikely. The substance is liquid and around 100°C during conditioning phase; sufficient RMM are already used during this phase, as workers are protected with intensive gloves, protective clothings and headgear as well as a local extraction ventilation. In addition, no acute toxic effects were identified in acute toxicity studies by oral and dermal routes. As this route of exposure is not significant and that no acute toxic effects are expected, an acute inhalation toxicity study is not deemed necessary.
Justification for selection of acute toxicity – dermal endpoint
Only one study available for this endpoint
Justification for classification or non-classification
Oral and dermal LD50 are higher than 2000 mg/kg bw in rats therefore Chimexane NV does not need to be classified for acute toxicity according to the Annex VI to the Directive 67/548/CEE and the CLP Regulation (EC) N° (1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.